194 related articles for article (PubMed ID: 12143270)
21. A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis--Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants.
Lin TY; Wang YH; Chang LY; Huang YC; Kao HT; Lin PY; Lu HK; Chavand P; Ortiz E
Int J Infect Dis; 2007 Mar; 11(2):129-36. PubMed ID: 16762579
[TBL] [Abstract][Full Text] [Related]
22. Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.
Sirivichayakul C; Chanthavanich P; Limkittikul K; Siegrist CA; Wijagkanalan W; Chinwangso P; Petre J; Hong Thai P; Chauhan M; Viviani S
Hum Vaccin Immunother; 2017 Jan; 13(1):136-143. PubMed ID: 27686283
[TBL] [Abstract][Full Text] [Related]
23. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity.
Ciarlet M; He S; Lai S; Petrecz M; Yuan G; Liu GF; Mikviman E; Heaton PM; Panzer F; Rose T; Koller DY; Van Damme P; Schödel F
Pediatr Infect Dis J; 2009 Mar; 28(3):177-81. PubMed ID: 19209092
[TBL] [Abstract][Full Text] [Related]
24. Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose.
Halperin SA; Donovan C; Marshall GS; Pool V; Decker MD; Johnson DR; Greenberg DP;
J Pediatric Infect Dis Soc; 2019 May; 8(2):105-114. PubMed ID: 29438562
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population.
Knuf M; Zepp F; Meyer C; Grzegowski E; Wolter J; Riffelmann M; Wirsing von König CH
Vaccine; 2006 Mar; 24(12):2043-8. PubMed ID: 16356597
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
Zepp F; Habermehl P; Knuf M; Mannhardt-Laakman W; Howe B; Friedland LR
Vaccine; 2007 Jul; 25(29):5248-52. PubMed ID: 17583395
[TBL] [Abstract][Full Text] [Related]
27. Interchangeability of two diphtheria and tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate vaccines as a fourth dose in 15-20-month-old toddlers.
Halperin SA; Tapiero B; Law B; Diaz-Mitoma F; Duval B; Langley JM; Elrick DB; Jacquet JM
Vaccine; 2006 May; 24(18):4017-23. PubMed ID: 16516357
[TBL] [Abstract][Full Text] [Related]
28. Effects of lowering the aluminium content of a dTpa vaccine on its immunogenicity and reactogenicity when given as a booster to adolescents.
Theeten H; Van Damme P; Hoppenbrouwers K; Vandermeulen C; Leback E; Sokal EM; Wolter J; Schuerman L
Vaccine; 2005 Feb; 23(12):1515-21. PubMed ID: 15670888
[TBL] [Abstract][Full Text] [Related]
29. Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4-5 years after a previous dose.
Halperin SA; McNeil S; Langley J; Blatter M; Dionne M; Embree J; Johnson R; Latiolais T; Meekison W; Noya F; Senders S; Zickler P; Johnson DR
Vaccine; 2011 Oct; 29(46):8459-65. PubMed ID: 21803091
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age.
Blatter M; Friedland LR; Weston WM; Li P; Howe B
Vaccine; 2009 Jan; 27(5):765-72. PubMed ID: 19041352
[TBL] [Abstract][Full Text] [Related]
31. A fourth dose of DTPa-IPV vaccine given to 4-6 year old children in Italy and Sweden following primary vaccination at 3, 5 and 11-12 months of age.
Nilsson L; Faldella G; Jacquet JM; Storsaeter J; Silfverdal SA; Ekholm L
Scand J Infect Dis; 2005; 37(3):221-9. PubMed ID: 15849057
[TBL] [Abstract][Full Text] [Related]
32. Kinetics of the antibody response to tetanus-diphtheria-acellular pertussis vaccine in women of childbearing age and postpartum women.
Halperin BA; Morris A; Mackinnon-Cameron D; Mutch J; Langley JM; McNeil SA; Macdougall D; Halperin SA
Clin Infect Dis; 2011 Nov; 53(9):885-92. PubMed ID: 21946190
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adults.
McNeil SA; Noya F; Dionne M; Predy G; Meekison W; Ojah C; Ferro S; Mills EL; Langley JM; Halperin SA
Vaccine; 2007 Apr; 25(17):3464-74. PubMed ID: 17270320
[TBL] [Abstract][Full Text] [Related]
34. Decennial administration in young adults of a reduced-antigen content diphtheria, tetanus, acellular pertussis vaccine containing two different concentrations of aluminium.
Vandermeulen C; Theeten H; Rathi N; Kuriyakose S; Han HH; Sokal E; Hoppenbrouwers K; Van Damme P
Vaccine; 2015 Jun; 33(26):3026-34. PubMed ID: 25613716
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity and safety of combined diphtheria tetanus whole cell pertussis hepatitis B/ Haemophilus influenzae type b vaccine in Indian infants.
Bavdekar SB; Maiya PP; Subba Rao SD; Datta SK; Bock HL
Indian Pediatr; 2007 Jul; 44(7):505-10. PubMed ID: 17684303
[TBL] [Abstract][Full Text] [Related]
36. Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose.
Halperin SA; Scheifele D; De Serres G; Noya F; Meekison W; Zickler P; Larrivée L; Langley JM; McNeil SA; Dobson S; Jordanov E; Thakur M; Decker MD; Johnson DR
Vaccine; 2012 Jan; 30(5):974-82. PubMed ID: 22115634
[TBL] [Abstract][Full Text] [Related]
37. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.
Trollfors B; Taranger J; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
Clin Infect Dis; 1999 Mar; 28(3):552-9. PubMed ID: 10194077
[TBL] [Abstract][Full Text] [Related]
38. IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content.
Hendrikx LH; Berbers GA; Veenhoven RH; Sanders EA; Buisman AM
Vaccine; 2009 Nov; 27(47):6530-6. PubMed ID: 19729085
[TBL] [Abstract][Full Text] [Related]
39. A comparison of booster immunisation with a combination DTPa-IPV vaccine or DTPa plus IPV in separate injections when co-administered with MMR, at age 4-6 years.
Marshall H; Nolan T; Roberton D; Richmond P; Lambert S; Jacquet JM; Schuerman L
Vaccine; 2006 Aug; 24(35-36):6120-8. PubMed ID: 16822597
[TBL] [Abstract][Full Text] [Related]
40. Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccines as a booster in 4-7-year-old children primed with diphtheria-tetanus-whole cell pertussis vaccine before 2 years of age.
Dagan R; Igbaria K; Piglansky L; Van Brusteghem F; Melot V; Kaufhold A
Vaccine; 1999 Jun; 17(20-21):2620-7. PubMed ID: 10418911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
